Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | FLT4 | P35916 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 8/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.47 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.47 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25735198 | 0.94 | CDK2 (0.53) | CDK2FLT4NAMPTKEAP1NFE2L2 | |
| SCHEMBL25735164 | 0.94 | CDK2 (0.53) | CDK2FLT4NAMPTKEAP1NFE2L2 | |
| SCHEMBL19834788 | 0.91 | KDM4E (0.51) | NAMPTKEAP1NFE2L2CYP3A4CYP2C9 | |
| SCHEMBL19834828 | 0.91 | PABPC1 (0.50) | NAMPTKEAP1NFE2L2CYP3A4CYP2C9 | |
| SCHEMBL19834785 | 0.86 | NAMPT (0.46) | CDK2FLT4NAMPTCYP3A4CYP2C9 | |
| SCHEMBL19834831 | 0.85 | NAMPT (0.67) | CDK2FLT4NAMPTKEAP1NFE2L2 | |
| SCHEMBL25735184 | 0.84 | PABPC1 (0.45) | NAMPTKEAP1NFE2L2SMN1; SMN2PABPC1 | |
| SCHEMBL25735183 | 0.84 | PABPC1 (0.45) | NAMPTKEAP1NFE2L2SMN1; SMN2PABPC1 | |
| SCHEMBL25735188 | 0.84 | PABPC1 (0.45) | NAMPTKEAP1NFE2L2SMN1; SMN2PABPC1 | |
| SCHEMBL25735148 | 0.84 | PABPC1 (0.45) | NAMPTKEAP1NFE2L2SMN1; SMN2PABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190185452-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV (CH) | 2019-06-20 | — | — | US | claimed |
| EP-3494111-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | Centre Hospitalier Universitaire Vaudois (CHUV) (CH) | 2019-06-12 | — | — | EP | claimed |
| WO-2018024907-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV (CH) | 2018-02-08 | — | — | WO | claimed |
| US-10894785-B2 | Piperidine derivatives for use in the treatment of pancreatic cancer | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV | 2021-01-19 | — | — | US | disclosed |
| US-10894785-B2 | Piperidine derivatives for use in the treatment of pancreatic cancer | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV | 2021-01-19 | — | — | US | disclosed |
| US-20190185452-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV (CH) | 2019-06-20 | — | — | US | disclosed |
| US-20190185452-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV (CH) | 2019-06-20 | — | — | US | disclosed |
| EP-3494111-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | Centre Hospitalier Universitaire Vaudois (CHUV) (CH) | 2019-06-12 | — | — | EP | disclosed |
| WO-2018024907-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV (CH) | 2018-02-08 | — | — | WO | disclosed |
| WO-2018024907-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV (CH) | 2018-02-08 | — | — | WO | disclosed |
| EP-3279192-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | Centre Hospitalier Universitaire Vaudois (CHUV) (CH) | 2018-02-07 | — | — | EP | disclosed |
| EP-3279192-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | Centre Hospitalier Universitaire Vaudois (CHUV) (CH) | 2018-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894785-B2 | Piperidine derivatives for use in the treatment of pancreatic cancer | RNASE1, PKD1, GPR6 | CDK2 702/4885FLT4 2161/4885NAMPT 1437/4885 |
| US-20190185452-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | RNASE1, PKD1, GPR6 | CDK2 594/4885FLT4 1716/4885NAMPT 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.